Tessa A Harland1, Joshua Seinfeld1, Andrew C White2, David A Kumpe3, Christopher D Roark1, David E Case1. 1. Department of Neurosurgery, University of Colorado School of Medicine, Aurora, CO, USA. 2. Department of Radiology, University of Louisville School of Medicine, Louisville, KY, USA. 3. Department of Radiology, University of Colorado School of Medicine, Aurora, CO, USA.
Abstract
OBJECTIVE: The second-generation pipeline embolization device (PED), flex, has improved opening and resheathing ability compared to the first-generation classic PED device. A previously reported single-institutional study suggests that the PED flex devices are associated with lower rates of complications. However, there was limited discussion regarding the complication rate with respect to microcatheter choice for PED delivery and deployment. The present study aims to evaluate outcomes of aneurysm treatment with PED flex versus classic along with the Phenom microcatheter versus Marksman microcatheter. METHODS: A retrospective, IRB-approved database of all patients who received a PED classic or PED flex device between January 2012 and July 2018 was analyzed. Microcatheter choice, patient demographics, medical comorbidities, aneurysm characteristics, treatment information, and outcome data were analyzed using univariate analyses. RESULTS: A total of 75 PED procedures were analyzed. There was no significant difference in major complications between the PED classic and PED flex. However, those treated using the Marksman microcatheter were more likely to have a major complication (periprocedural hemorrhage or ischemic event; 16.6% vs. 0%, p = 0.0248) than those treated with the Phenom microcatheter. Within the PED flex cohort, all major complications were associated with the Marksman microcatheter (p = 0.0289). CONCLUSIONS: The present study does not replicate significantly fewer complications with PED flex but demonstrates a significant reduction in complications with the Phenom microcatheter. Ultimately, this suggests multiple factors are involved in achieving positive outcomes and low complication rates in PED treated unruptured cerebral aneurysms. All Rights Reserved by JVIN. Unauthorized reproduction of this article is prohibited.
OBJECTIVE: The second-generation pipeline embolization device (PED), flex, has improved opening and resheathing ability compared to the first-generation classic PED device. A previously reported single-institutional study suggests that the PED flex devices are associated with lower rates of complications. However, there was limited discussion regarding the complication rate with respect to microcatheter choice for PED delivery and deployment. The present study aims to evaluate outcomes of aneurysm treatment with PED flex versus classic along with the Phenom microcatheter versus Marksman microcatheter. METHODS: A retrospective, IRB-approved database of all patients who received a PED classic or PED flex device between January 2012 and July 2018 was analyzed. Microcatheter choice, patient demographics, medical comorbidities, aneurysm characteristics, treatment information, and outcome data were analyzed using univariate analyses. RESULTS: A total of 75 PED procedures were analyzed. There was no significant difference in major complications between the PED classic and PED flex. However, those treated using the Marksman microcatheter were more likely to have a major complication (periprocedural hemorrhage or ischemic event; 16.6% vs. 0%, p = 0.0248) than those treated with the Phenom microcatheter. Within the PED flex cohort, all major complications were associated with the Marksman microcatheter (p = 0.0289). CONCLUSIONS: The present study does not replicate significantly fewer complications with PED flex but demonstrates a significant reduction in complications with the Phenom microcatheter. Ultimately, this suggests multiple factors are involved in achieving positive outcomes and low complication rates in PED treated unruptured cerebral aneurysms. All Rights Reserved by JVIN. Unauthorized reproduction of this article is prohibited.
Authors: Christoph J Griessenauer; Christopher S Ogilvy; Paul M Foreman; Michelle H Chua; Mark R Harrigan; Lucy He; Matthew R Fusco; J D Mocco; Christopher J Stapleton; Aman B Patel; Ashish Sonig; Adnan H Siddiqui; Ajith J Thomas Journal: Neurosurgery Date: 2017-04-01 Impact factor: 4.654
Authors: Tibor Becske; David F Kallmes; Isil Saatci; Cameron G McDougall; István Szikora; Giuseppe Lanzino; Christopher J Moran; Henry H Woo; Demetrius K Lopes; Aaron L Berez; Daniel J Cher; Adnan H Siddiqui; Elad I Levy; Felipe C Albuquerque; David J Fiorella; Zsolt Berentei; Miklós Marosfoi; Saruhan H Cekirge; Peter K Nelson Journal: Radiology Date: 2013-02-15 Impact factor: 11.105
Authors: Geoffrey P Colby; Matthew T Bender; Li-Mei Lin; Narlin Beaty; Justin M Caplan; Bowen Jiang; Erick M Westbroek; Bijan Varjavand; Jessica K Campos; Judy Huang; Rafael J Tamargo; Alexander L Coon Journal: J Neurosurg Date: 2018-12-01 Impact factor: 5.115
Authors: Pascal Jabbour; Nohra Chalouhi; Stavropoula Tjoumakaris; L Fernando Gonzalez; Aaron S Dumont; Ciro Randazzo; Robert M Starke; David Hasan; Rohan Chitale; Saurabh Singhal; Lea A Moukarzel; Robert Rosenwasser Journal: Neurosurgery Date: 2013-07 Impact factor: 4.654
Authors: David F Kallmes; Waleed Brinjikji; Edoardo Boccardi; Elisa Ciceri; Orlando Diaz; Rabih Tawk; Henry Woo; Pascal Jabbour; Felipe Albuquerque; Rene Chapot; Alain Bonafe; Shervin R Dashti; Josser E Delgado Almandoz; Curtis Given; Michael E Kelly; DeWitte T Cross; Gary Duckwiler; Nasser Razack; Ciaran J Powers; Sebastian Fischer; Demetrius Lopes; Mark R Harrigan; Daniel Huddle; Raymond Turner; Osama O Zaidat; Luc Defreyne; Vitor Mendes Pereira; Saruhan Cekirge; David Fiorella; Ricardo A Hanel; Pedro Lylyk; Cameron McDougall; Adnan Siddiqui; Istvan Szikora; Elad Levy Journal: Interv Neurol Date: 2016-05-26